Genmab — Oktober 2014
-
Nu også kun 14 dage til denne præsentation af Parren i San Diego: Progressing an Antibody-Drug Conjugate Targeting Tissue Factor for the Treatment of Solid Cancers.http://adc-summit.com/agenda/day-2
-
"Jannsen og Genmab meddeler at de har filet en NDA for Daratumumab mod behandling af R/R MM på baggrund af et igangværende phase II forsøg under BTD ordningen".... Så skal i se løjer når den tigger ind

-
på det rigtige tidspunkt er jeg aldrig bange for gearing i passende omfang..... men timing er alting

-
jeg skulle have solgt længere end de 5 kurspoint jeg tjente på mit lille trade, men var nu fint
500*5 kurspoint giver lige til et restaurantsbesøg efter skat -
og i + nu
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind